Staples JE, Kubota KA, Chalcraft LG, Mead PS, Petersen JM, 2006. Epidemiologic and molecular analysis of human tularemia, United States, 1964–2004. Emerg Infect Dis 12 :1113–1118.
Farlow J, Wagner DM, Dukerich M, Stanley M, Chu M, Kubota K, Petersen J, Keim P, 2005. Francisella tularensis in the United States. Emerg Infect Dis 11 :1835–1841.
Keim P, Johansson A, Wagner DM, 2007. Molecular epidemiology, evolution, and ecology of Francisella. Ann NY Acad Sci 1105 :30–66.
Hayes EB, 2005. Tularemia. Goodman JL, Dennis DT, Sonenshine DE, editors. Tick-Borne Diseases of Humans. Washington, DC: ASM Press, 207–217.
Jellison WL, 1974. Tularemia in North America, 1930–1974. Missoula, MT: University of Montana.
Eisen L, 2007. A call for renewed research on tick-borne Francisella tularensis in the Arkansas–Missouri primary national focus of tularemia in humans. J Med Entomol 44 :389–397.
Eisen RJ, Mead PS, Meyer AM, Pfaff LE, Bradley KK, Eisen L, 2008. Ecoepidemiology of tularemia in the southcentral United States. Am J Trop Med Hyg 78 :586–594.
Allred DM, Stagg GN, Lavender JF, 1956. Experimental transmission of Pastuerella tularensis by the tick, Dermacentor parumapertus. J Infect Dis 99 :143–145.
Bell JF, 1945. The infection of ticks (Dermacentor varibilis) with Pasteurella tularensis. J Infect Dis 76 :83–95.
Bell JF, Stewart SJ, Wikel SK, 1979. Resistance to tick-borne Francisella tularensis by tick-sensitized rabbits: allergic klendusity. Am J Trop Med Hyg 28 :876–880.
Hopla CE, 1953. Experimental studies on tick transmission of tularemia organisms. Am J Hyg 58 :101–118.
Parker RR, 1933. Recent studies of tick-borne diseases made at the United States Public Health Laboratory at Hamilton, Montana. Fifth Pacific Science Congress, Vancouver, Canada, June 1–4, 1933.
Parker RR, Spencer RR, Francis E, 1924. Tularemia infection in ticks of the species Dermacentor andersoni Stiles in the Bitterroot Valley, Montana. Public Health Rep 39 :1057–1073.
Philip CB, Jellison WL, 1934. The American dog tick, Dermacentor variabilis, as a host of Bacterium tularense. Public Health Rep 49 :386–392.
Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, McDade JE, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Tonat K, 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285 :2763–2773.
Dolan MC, Maupin GO, Panella NA, Golde WT, Piesman J, 1997. Vector competence of Ixodes scapularis, I. spinipalpis, and Dermacentor andersoni (Acari: Ixodidae) in transmitting Borrelia burgdorferi, the etiologic agent of Lyme disease. J Med Entomol 34 :128–135.
Sonenshine DE, 2005. The biology of tick vectors of human disease. Goodman JL, Dennis DT, Sonenshine DE, editors. Tick-Borne Diseases of Humans. Washington, DC: ASM Press, 12–36.
Conlan JW, Chen W, Shen H, Webb A, KuoLee R, 2003. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog 34 :239–248.
Chen W, Shen H, Webb A, KuoLee R, Conlan JW, 2003. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21 :3690–3700.
Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA, 1991. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun 59 :2922–2928.
Downs CM, Coriell LL, Pinchot GB, Maumenee E, Klauber A, Chapman SS, Owen B, 1947. I. The comparative susceptibility of various laboratory animals. J Immunol 56 :217–228.
KuoLee R, Zhao X, Austin J, Harris G, Conlan JW, Chen W, 2007. Mouse model of oral infection with virulent type A Francisella tularensis. Infect Immun 75 :1651–1660.
Twine SM, Shen H, Kelly JF, Chen W, Sjostedt A, Conlan JW, 2006. Virulence comparison in mice of distinct isolates of type A Francisella tularensis. Microb Pathog 40 :133–138.
Shen H, Chen W, Conlan JW, 2004. Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen. Vaccine 22 :2116–2121.
Cowley SC, Myltseva SV, Nano FE, 1997. Suppression of Francisella tularensis growth in the rat by co-infection with F. novicida. FRMS Microbiology Letters 153 :71–74.
Anthony LS, Skamene E, Kongshavn PA, 1988. Influence of genetic background on host resistance to experimental murine tularemia. Infect Immun 56 :2089–2093.
Balashov YS, 1968. Bloodsucking Ticks (Ixodoidea): Vectors of Disease of Man and Animals. Cairo, Egypt: US Naval Medical Research Unit 3.
Forestal CA, Malik M, Catlett SV, Savitt AG, Benach JL, Sellati TJ, Furie MB, 2007. Francisella tularensis has a significant extracellular phase in infected mice. J Infect Dis 196 :134–137.
Bell JF, 1980. Tularemia. Steele JH, editor. CRC Handbook Series in Zoonoses. Boca Raton, FL: CRC Press, 161–193.
Markowitz LE, Hynes NA, de la Cruz P, Campos E, Barbaree JM, Plikaytis BD, Mosier D, Kaufmann AF, 1985. Tick-borne tularemia. An outbreak of lymphadenopathy in children. JAMA 254 :2922–2925.
Schmid GP, Kornblatt AN, Connors CA, Patton C, Carney J, Hobbs J, Kaufmann AF, 1983. Clinically mild tularemia associated with tick-borne Francisella tularensis. J Infect Dis 148 :63–67.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||176||82||1|
Tularemia is a tick-borne zoonotic bacterial disease. In the United States, human tularemia infections are caused by Francisella tularensis subspecies tularensis (Type A, clades A1 and A2) or F. tularensis subspecies holarctica (Type B). We developed a mouse model that can be used to study the ability of ticks to acquire and transmit fully virulent strains of F. tularensis (A1, A2, and Type B). We showed that 1) bacteremia was evident by 2 days post-infection (dpi) for A1, A2, and B, 2) bacteremia was expected to reach levels of > 108 cfu/mL by 3 dpi for A1 and A2 but not until 4 dpi for Type B, and 3) illness onset was delayed for mice exposed to Type B compared with A1 and A2. To maximize the likelihood of ticks acquiring infection from laboratory-infected mice before they become moribund and must be euthanized, ticks should be placed on mice so that periods of rapid engorgement occur 3–4 dpi for A1 and A2 and 4–5 dpi for Type B. Rigorous experimental studies of tick vector competence and efficiency conducted under standardized conditions are required to address several significant public health issues related to preventing and controlling tularemia. Our study provides the basis for a mouse model needed as the starting point to address these questions.